Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04356495
PHASE2/PHASE3

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation

Sponsor: University Hospital, Bordeaux

View on ClinicalTrials.gov

Summary

In adults with COVID-19 without criteria for hospitalization or oxygen therapy but with risk factors for aggravation, early treatment may avoid hospitalization, indication for oxygen therapy or death. No treatment is currently validated for this indication.

Official title: Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France)

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

412

Start Date

2020-07-29

Completion Date

2021-10-22

Last Updated

2026-05-12

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Vitamins

2 tablets daily from the first day (day 0) to day 9

DRUG

Telmisartan

1 tablet daily from the first day (day 0) to day 9

DRUG

Ciclesonide

2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9

DRUG

interferon β-1b

A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water

Locations (7)

Bordeaux university Hospital

Bordeaux, France

CHU de Dijon-Bourgogne

Dijon, France

CHU de Montpellier

Montpellier, France

CHRU de Nancy

Nancy, France

Groupe hospitalier Paris Saint Joseph

Paris, France

CNGE

Paris, France

CHU de Toulouse

Toulouse, France